Medtronic Announces Successes in Bronchoscopy Study for Lung Cancer

superDimension System, Medtronic

Register to receive a free U.S. Market for ENT and Bronchoscopic Devices Report Suite report synopsis and brochure

The Journal of Thoracic Oncology has published the results of a year-long study NAVIGATE. The NAVIGATE study is the largest trial in assessing the nuances of electromagnetic navigation bronchoscopy (ENB) procedures using the superDimension™ system. The study announced that 65% of lung cancer patient diagnoses by physicians were at Stage I or Stage II of the disease, which is significant in securing long-term patient health due to the aggressive nature of lung cancer.

ENB procedures offer a minimally invasive way to access secluded areas in the lungs by utilizing a GPS-esque technology. As ENB increases the likelihood of earlier, personalized treatment, it is likely to ensure patient health in the long term since earlier treatment is correlated to improved survival rates. Additionally, the minimally invasive nature of ENB has proven to limit complications with an observed reduction in pneumothorax rates in the NAVIGATE study when compared to typical transthoracic needle biopsies. The NAVIGATE study found that 49% of lesions detected in ENB procedures were smaller than 20 mm in diameter, indicating that ENB is capable of evaluating and detecting small peripheral lesions.

The American Cancer Society states that lung cancer is the leading cause of cancer-related deaths in the United States. Long-term survival rates decline severely when diagnosis occurs late, at Stage III or IV. These stages are where the majority of lung cancer patients today are diagnosed. However, with early detection and diagnosis at Stage I, the estimated 10-year patient survival rate rises to 88%.

ENT and Bronchoscopy Market Research published by iData Research indicates that the bronchoscope market has been experiencing increasing demand for lung cancer diagnosis devices. As the age of the U.S. population gradually increases, the demand for lung cancer screening is expected to increase further. As such, minimally invasive and reliable bronchoscopy innovations such as ENB are projected to lead to significant growth in their segments.

“These data demonstrate that, for the first time, both academic and community-based care clinicians can safely obtain a diagnosis in small, peripheral lung lesions, and then stage and prepare for future treatment in a single minimally invasive procedure,” said Erik Folch, M.D., M.Sc., chief of the Complex Chest Disease Center and co-director of Interventional Pulmonology at Massachusetts General Hospital in Boston, and co-lead investigator of the NAVIGATE study. “NAVIGATE is the first large, multicenter study to evaluate ENB diagnostic yield and complication rates with prospective, long-term follow up of negative cases. Because we looked at all cases-not just those with easily accessible lesions-NAVIGATE replicates real-world conditions and demonstrates that ENB has the potential to significantly accelerate lung cancer detection, and consequently improve the likelihood of a successful intervention.”

For Further Information
More on the bronchoscope market in the U.S. can be found in a report suite published by iData Research entitled the U.S. Market for ENT and Bronchoscopic Devices Report Suite.

Leave a Reply